(1-Methyl-2-nitro-1H-imidazol-5-yl)methanol, 95.0%, 250mg

(2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-methylbutanamido]-5-(carbamoylamino)pentanoic acid, 98%, 100g

2-Amino-3-(5-fluoro-2-nitrophenyl)propanoic acid hydrochloride, 98%, 1g

2,6-Dimethoxybenzamide, 97%, 250mg

(2E)-1-(2,4-dimethoxyphenyl)-3-(2,3,4-trimethoxyphenyl)prop-2-en-1-one, 95.0%, 2g

4-Methoxy-3-nitrophenylboronic acid, 95.0%, 250mg

Combretastatin A4>98.0%(HPLC)250mg

4-amino-N-(3-chlorophenyl)benzamide, 95.0%, 1g

Carbamic acid, [(3S)-1-[[[3-(trifluoromethyl)benzoyl]amino]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester, 97%, 250mg

2-Amino-4,4,4-trifluorobutanoic acid hydrochloride, 95+%, 100mg

3-(Chloromethyl)-1-methyl-1H-pyrazole, 95.0%, 10g

N,N'-Bis(salicylidene)-1,2-phenylenediamine>96.0%(HPLC)(N)25g

(S)-3-Hydroxy-2-(methylamino)propanoic acid, 95.0%, 250mg